Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4 (2013) O’Shannessy DJ, Somers EB, Palmer LM, Thiel RP, Oberoi P, Heath R, Marcucci L Journal of Ovarian Research 2013, 6:29

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors (2012) Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ J Clin Oncol. 2012 Apr 23

Supernatants derived from chemotherapy-treated cancer cell lines can modify angiogenesis (2012) Liu WM, Dennis JL, Gravett AM, Chanthirakumar C, Kaminska E, Coulton G, Fowler DW, Bodman-Smith M, Dalgleish AG Br J Cancer. 2012 Jan 31 [Epub ahead of print]

STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma (2012) Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, MacKeigan JP PLoS ONE 7(2): e30820

Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes (2012) Willard MD, Lajiness ME, Wulur IH, Feng B, Swearingen ML, Uhlik MT, Kinzler KW, Velculescu VE, Sjöblom T, Markowitz SD, Powell SM, Vogelstein B, Barber TD Mol Cancer Res. 2012 Apr 19

Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma (2012) Xu BJ, An QA, Srinivasa Gowda S, Yan W, Pierce LA, Abel TW, Rush SZ, Cooper MK, Ye F, Shyr Y, Weaver KD, Thompson RC Int J Oncol. 2012 Jun;40(6):1995-2003

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival (2012) Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H Nat Med. 2012 Jul 29. doi: 10.1038/nm.2883. [Epub ahead of print]

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences (2012) Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH, Rule SA Br J Haematol. 2012 Aug 9.

A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia (2012) Ghobrial IM, Moreau P, Harris B, Poon T, Jourdan E, Maisonneuve HM, Benhadji KA, Hossain A, Nguyen T, Wooldridge JE, Leblond V Clin Cancer Res. 2012 Aug 9

Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice (2012) Donat U, Weibel S, Hess M, Stritzker J, Härtl B, Sturm JB, Chen NG, Gentschev I, Szalay AA PLoS ONE 7(9): e45942

Identification of factors associated with cancer related fatigue syndrome in disease-free breast cancer patients after completing primary treatment (2012) Minton O, Alexander S, Stone PC Breast Cancer Res Treat. 2012 Oct 14. [Epub ahead of print]

Preferential Replication of Systemically Delivered Oncolytic Vaccinia Virus in Focally Irradiated Glioma Xenografts (2012) Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, Yu YA, Aguilar RJ, Mundt A, Szalay AA Clin Cancer Res. 2012 Feb 29. [Epub ahead of print]

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma (2011) Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL, Laubach JP, Anderson KC, Desaiah D, Myrand SP, Wooldridge JE, Richardson PG, Abonour R Am. J. Hematol.

Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays (2011) Sauer G, Schneiderhan-Marra N, Muche R, Koretz K, Kazmaier C, Kreienberg R, Joos T, Deissler H J Cancer Res Clin Oncol. 2011 Apr 24. [Epub ahead of print]

Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells (2011) Hsieh YH, Juliana MM, Ho KJ, Kuo HC, van der Heyde H, Elmets C, Chang PL Int J Cancer. 2011 Aug 8. doi: 10.1002/ijc.26359. [Epub ahead of print]

Tumor Microenvironment-Derived Proteins Dominate the Plasma Proteome Response During Breast Cancer Induction and Progression (2011) Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Busald Buson T, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ Cancer Res. 2011 Jun 8. [Epub ahead of print]

Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68 (2011) Gentschev I, Müller M, Adelfinger M, Weibel S, Grummt F, Zimmermann M, Bitzer M, Heisig M, Zhang Q, Yu YA, Chen NG, Stritzker J, Lauer UM, Szalay AA PLoS ONE 6(7): e22069

STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia (2011) Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, Zimmers TA PLoS ONE 6(7): e22538

Mycobacteria activate gamma delta T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy (2011) Fowler DW, Copier J, Wilson N, Dalgleish AG, Bodman-Smith MD Cancer Immunol Immunother. 2011 Oct 15. [Epub ahead of print]

Bone Marrow Derived Mesenchymal Stromal Cells are Attracted by Multiple Myeloma Cell-Produced Chemokine CCL25 and Favor Myeloma Cell Growth In Vitro and In Vivo (2011) Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I Stem Cells. 2011 Nov 18. [Epub ahead of print]

A novel detection method of non-small cell lung cancer using multiplexed bead-based serum biomarker profiling (2011) Lee HJ, Kim YT, Park PJ, Shin YS, Kang KN, Kim Y, Kim CW J Thorac Cardiovasc Surg. 2011 Nov 18. [Epub ahead of print]

Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers (2011) Yip P, Chen TH, Seshaiah P, Stephen LL, Michael-Ballard KL, Mapes JP, Mansfield BC, Bertenshaw GP PLoS One. 2011;6(12):e29533. Epub 2011 Dec 21

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial (2011) Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM Lancet Oncol. 2011 Nov;12(12):1125-33

High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the gamma-secretase inhibitor, RO4929097 (2011) He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X, Cai J, Higgins B, Kolinsky K, Rizzo C, Packman K, Heimbrook D, Boylan JF Molecular Oncology [Epub ahead of print]

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells (2011) Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G Nature. 2011 Jul 13;475(7355):226-30

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. (2010) Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F J Clin Oncol 28: 1181-1189.

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours (2010) Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, Del Maschio A, Esposito A, De Cobelli F, Dell’Acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C Eur J Cancer. 46: 198-206.

Identification of breast cancer biomarkers in transgenic mouse models: a proteomics approach. (2010) Rodenburg W, Pennings JLA, van Oostrom CTM, Roodbergen M, Kuiper RV, Luijten M, de Vries A Proteomics Clin Appl. 4: 602-612.

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma. (2010) Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT Cancer Res 70: 1063-1071.

Significant growth inhibition of canine mammary carcinoma xenografts following treatment with oncolytic vaccinia virus GLV-1h68 (2010) Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I, Stritzker J, Szalay AA J Oncol. 2010:736907. Epub 2010 Jun 23

Validation of a Multivariate Serum Profile for Epithelial Ovarian Cancer Using a Prospective Multi-Site Collection (2010) Seshaiah P, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, Mapes JP, Stephen LL, Amonkar S, McCollum ME, Miller BE, Roman LD, Karlan BY, Chalas E, DiSilvestro PA, Barter JF, Orr Jr JW, Bigsby IV GE, Holloway RW, Alvarez RD, Yip PF, Mansfield BC Nature Precedings Jul 2010.

A phase 2 pilot trial of low-dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma. (2010) Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP Cancer 116: 1751-1756.

Development and Preliminary Evaluation of a Multivariate Index Assay for Ovarian Cancer. (2009) Amonkar SD, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, Seshaiah P, Yip P, Mansfield BC PLoS ONE 4: e4599.

The multiplex bead array approach to identifying serum biomarkers associated with breast cancer (2009) Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, Ye S, Hyun H, Kang KN, Yeo D, Kim Y, Ohn SY, Noh DY, Kim CW Breast Cancer Res. 11: R22.

Western-style diets induce oxidative stress and dysregulate immune responses in the colon in a mouse model of sporadic colon cancer (2009) Erdelyi I, Levenkova N, Lin EY, Pinto JT, Lipkin M, Quimby FW, Holt PR J Nutr. 139: 2072-8.

Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer. (2009) Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O, De Moor B, Tejpar S, McBride WH, Penninckx F, Scalliet P, Stroh C, Vlassak S, Sempoux C, Machiels JP J Clin Oncol 27: 2751-2757.

Regression of Human Pancreatic Tumor Xenografts in Mice After a Single Systemic Injection of Recombinant Vaccinia Virus GLV-1h68. (2009) Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, Szalay AA Mol Cancer Ther 8: 141-151.

Immune Activation in Advanced Cancer Patients Treated with Recombinant IL-21: Multianalyte Profiling of Serum Proteins. (2009) Dodds MG, Frederiksen KS, Skak K, Hansen LT, Lundsgaard D, Thompson JA, Hughes SD Cancer Immunol Immunother 58: 843-854.

Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer. (2009) Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, Mogenet A, Bresson JL, Prié D, Béchet S, Baron C, Sadorge C, Thomas S, Albert EB, Albert PS, Albert ML J Urol 181: 1571-1580.

Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. (2008) Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, Mansfield BC Cancer Epidemiol Biomarkers Prev 17: 2872-81.

Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. (2008) Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang Z, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH, Duesbery NS Mol Cancer Ther 7: 648-658.

A mouse to human search for plasma proteome changes associated with pancreatic tumor development. (2008) Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM PLoS Med 5: e123.

Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. (2008) Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G J Clin Oncol 26: 1135-1141.

TGF-beta signalling-related markers in cancer patients with bone metastasis. (2008) Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M Biomarkers 13: 217-236.

Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. (2007) Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, Defresne MP, Van Riet I, Van Camp B, Vanderkerken K Leukemia 21: 1580-1584.

Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. (2006) Singh M, Johnson L Clin Cancer Res 12: 5312-5328.

Effects of the incubation in vitro with sorbents on serum proteomic pattern and cytokine concentration in cancer patients during chemotherapy–preliminary results. (2006) Piccolomini F, LouWratten M, Sereni L, Balestreri E, Donadio E, Felicioli A, Felicioli R, Donadio C Biomed Pharmacother 60: 463-467.